These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 24906571

  • 1. [The impact of donor naive and memory T cell subsets on patient outcome following allogeneic stem cell transplantation: relationship between infused donor CD4+/CCR7+ T cell subsets and acute graft-versus-host disease].
    Choufi B, Thiant S, Trauet J, Cliquennois M, Cherrel M, Boulanger F, Coiteux V, Magro L, Labalette M, Yakoub-Agha I.
    Pathol Biol (Paris); 2014 Jun; 62(3):123-8. PubMed ID: 24906571
    [Abstract] [Full Text] [Related]

  • 2. A high proportion of donor CD4+ T cells expressing the lymph node-homing chemokine receptor CCR7 increases incidence and severity of acute graft-versus-host disease in patients undergoing allogeneic stem cell transplantation for hematological malignancy.
    Yakoub-Agha I, Saule P, Depil S, Micol JB, Grutzmacher C, Boulanger-Villard F, Bauters F, Jouet JP, Dessaint JP, Labalette M.
    Leukemia; 2006 Sep; 20(9):1557-65. PubMed ID: 16826221
    [Abstract] [Full Text] [Related]

  • 3. Comparative analysis of naïve and memory CD4+ and CD8+ T-cell subsets in bone marrow and G-CSF-mobilized peripheral blood stem cell allografts: impact of donor characteristics.
    Yakoub-Agha I, Saule P, Depil S, Grutzmacher C, Boulanger F, Magro L, Jouet JP, Dessaint JP, Labalette M.
    Exp Hematol; 2007 Jun; 35(6):861-71. PubMed ID: 17533040
    [Abstract] [Full Text] [Related]

  • 4. Immunomagnetic selective donor-derived CD4+CCR7+ T cell depletion procedure for peripheral blood stem cells graft.
    Varlet P, Rogeau S, Trauet J, Demaret J, Labalette M.
    Curr Res Transl Med; 2019 Feb; 67(1):1-7. PubMed ID: 30665880
    [Abstract] [Full Text] [Related]

  • 5. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ, Mauch P, Fairclough D, Alyea E, Anderson K, Fisher D, Freedman A, Bartlett-Pandite L, Robertson M, Schlossman R, Gollob J, Marcus K, Murray C, Kuhlman C, Freeman A, Nadler L, Ritz J.
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [Abstract] [Full Text] [Related]

  • 6. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD, Becker EE, Truitt RL.
    Biol Blood Marrow Transplant; 1999 Apr; 5(3):123-32. PubMed ID: 10392958
    [Abstract] [Full Text] [Related]

  • 7. Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children.
    Kałwak K, Porwolik J, Mielcarek M, Gorczyńska E, Owoc-Lempach J, Ussowicz M, Dyla A, Musiał J, Paździor D, Turkiewicz D, Chybicka A.
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1388-401. PubMed ID: 20382248
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F.
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [Abstract] [Full Text] [Related]

  • 10. Immune cell subset counts associated with graft-versus-host disease.
    Podgorny PJ, Liu Y, Dharmani-Khan P, Pratt LM, Jamani K, Luider J, Auer-Grzesiak I, Mansoor A, Williamson TS, Ugarte-Torres A, Hoegh-Petersen M, Stewart DA, Daly A, Khan FM, Russell JA, Storek J.
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):450-62. PubMed ID: 24406506
    [Abstract] [Full Text] [Related]

  • 11. [T-cell-depleted HLA non-identical bone marrow transplantation in the child: prevention of graft-versus-host reaction by administration of donor T lymphocytes alloreactive against the recipient].
    Cavazzana-Calvo M, André-Schmutz I, Hacein-Bey S, Schindler J, Vitetta H, Dupuis S, Quartier P, Chedeville G, Vilmer E, Casanova JL, Buffet R, Caillat-Zucman S, Radford I, Le Deist F, Fischer A.
    J Soc Biol; 2001 Apr; 195(1):65-8. PubMed ID: 11530503
    [Abstract] [Full Text] [Related]

  • 12. Naïve subset develops the most important alloreactive response among human CD4+ T lymphocytes in human leukocyte antigen-identical related setting.
    Chérel M, Choufi B, Trauet J, Cracco P, Dessaint JP, Yakoub-Agha I, Labalette M.
    Eur J Haematol; 2014 Jun; 92(6):491-6. PubMed ID: 24520815
    [Abstract] [Full Text] [Related]

  • 13. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
    Gallardo D, García-López J, Sureda A, Canals C, Ferra C, Cancelas JA, Berlanga JJ, Brunet S, Boqué C, Picón M, Torrico C, Amill B, Martino R, Martínez C, Martín-Henao G, Domingo-Albós A, Grañena A.
    Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
    [Abstract] [Full Text] [Related]

  • 14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Orti G, Lowdell M, Fielding A, Samuel E, Pang K, Kottaridis P, Morris E, Thomson K, Peggs K, Mackinnon S, Chakraverty R.
    Transplantation; 2009 Dec 15; 88(11):1312-8. PubMed ID: 19996931
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Immunomonitoring of graft-versus-host minor histocompatibility antigen correlates with graft-versus-host disease and absence of relapse after graft.
    Laurin D, Hannani D, Pernollet M, Moine A, Plumas J, Bensa JC, Cahn JY, Garban F.
    Transfusion; 2010 Feb 15; 50(2):418-28. PubMed ID: 19843288
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T, Taniguchi Y, Hasei H, Kaida K, Inoue T, Kim EH, Kawase I.
    Biol Blood Marrow Transplant; 2006 Oct 15; 12(10):1073-84. PubMed ID: 17084371
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.